CG Oncology, Inc. Common stock (CGON) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
6.27
↑+87% vs avg
5yr avg: 3.35
30Y Low2.4·High4.3
ROE
↑
-21.7%
↓+26% vs avg
5yr avg: -29.4%
30Y Low-43%·High-19%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CGON Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CG Oncology, Inc. Common stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $5.4B | $3.2B | $1.8B | — | — | — |
| Enterprise Value | $5.4B | $3.2B | $1.5B | — | — | — |
| P/E Ratio → | -29.37 | — | — | — | — | — |
| P/S Ratio | 1333.52 | 794.47 | 1573.67 | — | — | — |
| P/B Ratio | 6.27 | 4.26 | 2.44 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CGON EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 788.16 | 1348.18 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
CGON Profitability
Margins and return-on-capital ratios measuring operating efficiency
CG Oncology, Inc. Common stock earns an operating margin of -4722.1%. Operating margins have expanded from -27180.9% to -4722.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -21.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | -15.0% | -15.0% | 100.0% | 100.0% | 92.1% | 99.9% |
| Operating Margin | -4722.1% | -4722.1% | -10067.3% | -27180.9% | -18453.4% | -121.7% |
| Net Profit Margin | -3985.0% | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -21.7% | -21.7% | -19.2% | -31.4% | -42.8% | -31.9% |
| ROA | -20.8% | -20.8% | -18.5% | -28.0% | -34.3% | -21.9% |
| ROIC | -23.8% | -23.8% | -26.3% | -36.1% | -96.6% | — |
| ROCE | -25.5% | -25.5% | -25.0% | -34.9% | -38.1% | -23.9% |
CGON Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $32M exceeds total debt of $7M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.13 | 0.38 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.03 | -0.35 | -0.04 | -0.58 | -0.96 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -35246.00 | -27.47 |
Net cash position: cash ($32M) exceeds total debt ($7M)
CGON Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
CG Oncology, Inc. Common stock's current ratio of 24.63x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 13.62x to 24.63x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 24.63 | 24.63 | 35.30 | 13.62 | 9.54 | 9.78 |
| Quick Ratio | 24.58 | 24.58 | 35.30 | 13.62 | 9.54 | 9.78 |
| Cash Ratio | 24.07 | 24.07 | 34.72 | 13.17 | 9.30 | 8.97 |
| Asset Turnover | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.18 |
| Inventory Turnover | 2.97 | 2.97 | — | — | — | — |
| Days Sales Outstanding | — | 62.16 | 250.28 | 164.61 | 579.03 | 0.07 |
CGON Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CG Oncology, Inc. Common stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $77M | $62M | $67M | $67M | $67M |
Peer Comparison
Compare CGON with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CGONYou | $5B | -29.4 | — | — | -15.0% | -4722.1% | -21.7% | -23.8% | — |
 GRVY | $455M | 10.2 | 5.4 | 9.1 | 35.0% | 14.2% | 11.2% | 15.5% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 TGTX | $8B | 19.2 | 67.4 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 JANX | $867M | -7.8 | — | — | 79.7% | -1576.7% | -11.5% | -15.3% | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 IMCR | $1B | -54.0 | — | — | 97.9% | -11.3% | -7.1% | -17.2% | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ADCT | $139M | -1.0 | — | — | 90.6% | -133.2% | — | — | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CGON — Frequently Asked Questions
Quick answers to the most common questions about buying CGON stock.
What is CG Oncology, Inc. Common stock's P/E ratio?
CG Oncology, Inc. Common stock's current P/E ratio is -29.4x. This places it at the 50th percentile of its historical range.
What is CG Oncology, Inc. Common stock's ROE?
CG Oncology, Inc. Common stock's return on equity (ROE) is -21.7%. The historical average is -29.4%.
Is CGON stock overvalued?
Based on historical data, CG Oncology, Inc. Common stock is trading at a P/E of -29.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are CG Oncology, Inc. Common stock's profit margins?
CG Oncology, Inc. Common stock has -15.0% gross margin and -4722.1% operating margin.